DDInter1742 DDInter1376
Talazoparib is an inhibitor of mammalian polyadenosine 5’-diphosphoribose polymerases (PARPs), enzymes responsible for regulating essential cellular functions, such as DNA transcription and DNA repair. Developed by Pfizer, talazoparib was first approved by the FDA in October 2018 and by the EMA in June 2019. It was approved by Health Canada in September 2020. Talazoparib is currently used in the treatment of BRCA-mutated breast cancer and HRR-mutated prostate cancer.[L47236, L47301, L47306]
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Talazoparib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Simeprevir
Talazoparib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Human adenovirus e serotype 4 strain cl-68578 antigen
Talazoparib {u} may lead to a major life threatening interaction when taken with {v} Measles virus vaccine live attenuated
Talazoparib {u} may lead to a major life threatening interaction when taken with {v} Smallpox (Vaccinia) Vaccine, Live
Talazoparib may cause a moderate interaction that could exacerbate diseases when taken with Simeprevir
Talazoparib may cause a moderate interaction that could exacerbate diseases when taken with Human adenovirus e serotype 4 strain cl-68578 antigen
Talazoparib may lead to a major life threatening interaction when taken with Measles virus vaccine live attenuated
Talazoparib may lead to a major life threatening interaction when taken with Smallpox (Vaccinia) Vaccine, Live